Fennec Pharmaceuticals has rebounded to near 52-week highs after PEDMARK drove the business to profitability, easing dilution fears. Despite 78% Y/Y net sales growth and a positive Q2 net income, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results